Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

GLP1 pills vs. injections: Which works better, and what are the side effects? (opens in a new tab)

ktla.com · 2026-06-07

Short answerEvidenceSource

Short answer

Several possible studies

No confirmed study match.

Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.

19 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

The literature search

19 candidate papers

Papers surfaced in our search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 15 more search results
Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 8Not checkedGLP-1 drugs are now available in pill form from Eli Lilly and Novo Nordisk, rather than only as injections.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 8Not checkedEarly studies show the pills are not quite as effective as injectable GLP-1 medications for weight loss.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 8Not checkedIn one clinical trial of more than 3,000 people, the oral GLP-1 pill orforglipron led to an average loss of about 25 pounds, or 11% of body weight, over 72 weeks, compared with less than 5 pounds, or about 2%, for placebo.View evidenceHide evidence

As statedabout 25 pounds / 11% vs less than 5 pounds / 2%

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 8Not checkedThe article says clinical trials of injectable Zepbound and Wegovy showed greater average weight loss than the oral pill, with participants losing 50 pounds on average on Zepbound and 33 pounds on average on Wegovy.View evidenceHide evidence

As stated50 pounds and 33 pounds on average

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 8Not checkedFor type 2 diabetes, the article says oral semaglutide may produce bigger reductions in blood sugar than the injectable version, even when the injectable form causes more weight loss.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 8Not checkedA study comparing oral semaglutide with injectable semaglutide found a significantly higher risk of treatment discontinuation due to side effects among patients receiving the oral form.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 7 of 8Not checkedThe article says the most commonly reported side effects in injectable GLP-1 trials were gastrointestinal, including nausea, constipation, diarrhea and vomiting.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 8 of 8Not checkedThe article says self-pay prices for the oral medications start at $149 per month, while self-pay prices for injections are higher, with Wegovy and Zepbound listed at $199 to $449 per month depending on dose and offer.View evidenceHide evidence

As stated$149 per month; $199 to $449 per month

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

Crossref, PubMed, Europe PMC · 17 candidate papers

Explore all search results